Literature DB >> 20044052

A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects.

Thomas R Cate1, Yolanda Rayford, Diane Niño, Patricia Winokur, Rebecca Brady, Robert Belshe, Wilbur Chen, Robert L Atmar, Robert B Couch.   

Abstract

Antibody to the neuraminidase (NA) antigen of influenza viruses has been shown to correlate with immunity to influenza in humans and animal models. In a previous report, we showed that an inactivated influenza vaccine containing 60microg of the hemagglutinin (HA) of each strain induced significantly more serum anti-HA antibody among elderly persons than did the standard vaccine containing 15microg of the HA of each component. We developed a lectin-based assay for anti-NA antibody and used it to measure anti-NA antibody responses among subjects who had participated in that study. The high dosage vaccine contained eight times as much NA activity as the standard vaccine and induced a significantly higher frequency of antibody responses and higher mean postvaccination anti-NA titers to the N1 and N2 of the A/H1N1 and A/H3N2 viruses in the vaccines than did the standard vaccine. Ensuring an increased antibody response to the NA antigen in inactivated influenza virus vaccines should increase the protection against influenza. An increased quantity of the NA antigen in the vaccine will ensure an increased response. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20044052      PMCID: PMC2853016          DOI: 10.1016/j.vaccine.2009.12.041

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  18 in total

Review 1.  Neuraminidase inhibitors for influenza.

Authors:  Anne Moscona
Journal:  N Engl J Med       Date:  2005-09-29       Impact factor: 91.245

2.  Measurement of anti-influenza neuraminidase antibody using a peroxidase-linked lectin and microtitre plates coated with natural substrates.

Authors:  C R Lambré; H Terzidis; A Greffard; R G Webster
Journal:  J Immunol Methods       Date:  1990-12-31       Impact factor: 2.303

3.  Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects.

Authors:  Robert B Couch; Patricia Winokur; Rebecca Brady; Robert Belshe; Wilbur H Chen; Thomas R Cate; Bryndis Sigurdardottir; Amy Hoeper; Irene L Graham; Robert Edelman; Fenhua He; Diane Nino; Jose Capellan; Frederick L Ruben
Journal:  Vaccine       Date:  2007-09-14       Impact factor: 3.641

4.  Protective immunity afforded by inactivated H5N1 (NIBRG-14) vaccine requires antibodies against both hemagglutinin and neuraminidase in mice.

Authors:  Yoshimasa Takahashi; Hideki Hasegawa; Yukari Hara; Manabu Ato; Ai Ninomiya; Hirotaka Takagi; Takato Odagiri; Tetsutaro Sata; Masato Tashiro; Kazuo Kobayashi
Journal:  J Infect Dis       Date:  2009-06-01       Impact factor: 5.226

5.  Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults.

Authors:  D C Powers; E D Kilbourne; B E Johansson
Journal:  Clin Diagn Lab Immunol       Date:  1996-09

6.  Neuraminidase antibody response to inactivated influenza virus vaccine following intranasal and intramuscular vaccination.

Authors:  Gaber Muhamed; Evgenia Greenbaum; Zichria Zakay-Rones
Journal:  Isr Med Assoc J       Date:  2006-03       Impact factor: 0.892

Review 7.  An overview of serum antibody responses to influenza virus antigens.

Authors:  R B Couch
Journal:  Dev Biol (Basel)       Date:  2003

Review 8.  Seasonal inactivated influenza virus vaccines.

Authors:  Robert B Couch
Journal:  Vaccine       Date:  2008-09-12       Impact factor: 3.641

9.  Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection.

Authors:  K Mozdzanowska; K Maiese; M Furchner; W Gerhard
Journal:  Virology       Date:  1999-02-01       Impact factor: 3.616

10.  Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins.

Authors:  E D Kilbourne; B E Johansson; B Grajower
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

View more
  55 in total

1.  Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses.

Authors:  Matthew R Sandbulte; Kim B Westgeest; Jin Gao; Xiyan Xu; Alexander I Klimov; Colin A Russell; David F Burke; Derek J Smith; Ron A M Fouchier; Maryna C Eichelberger
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

2.  Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice.

Authors:  Judith D Easterbrook; Louis M Schwartzman; Jin Gao; John C Kash; David M Morens; Laura Couzens; Hongquan Wan; Maryna C Eichelberger; Jeffery K Taubenberger
Journal:  Virology       Date:  2012-06-22       Impact factor: 3.616

3.  Randomized, controlled trial of high-dose influenza vaccine among frail residents of long-term care facilities.

Authors:  David A Nace; Chyongchiou Jeng Lin; Ted M Ross; Stacey Saracco; Roberta M Churilla; Richard K Zimmerman
Journal:  J Infect Dis       Date:  2014-12-17       Impact factor: 5.226

4.  Influenza vaccine effectiveness in households with children during the 2012-2013 season: assessments of prior vaccination and serologic susceptibility.

Authors:  Suzanne E Ohmit; Joshua G Petrie; Ryan E Malosh; Alicia M Fry; Mark G Thompson; Arnold S Monto
Journal:  J Infect Dis       Date:  2014-11-21       Impact factor: 5.226

Review 5.  Fast vaccine design and development based on correlates of protection (COPs).

Authors:  Cécile van Els; Siri Mjaaland; Lisbeth Næss; Julia Sarkadi; Eva Gonczol; Karen Smith Korsholm; Jon Hansen; Jørgen de Jonge; Gideon Kersten; Jennifer Warner; Amanda Semper; Corine Kruiswijk; Fredrik Oftung
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

6.  Individual antibody and T cell responses to vaccination and infection with the 2009 pandemic swine-origin H1N1 influenza virus.

Authors:  Gillian M Air; Jingqi Feng; Tao Chen; Michelle L Joachims; Judith A James; Linda F Thompson
Journal:  J Clin Immunol       Date:  2011-07-06       Impact factor: 8.317

7.  Neuraminidase, the Forgotten Surface Antigen, Emerges as an Influenza Vaccine Target for Broadened Protection.

Authors:  Maryna C Eichelberger; Arnold S Monto
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

Review 8.  Evaluating the case for trivalent or quadrivalent influenza vaccines.

Authors:  David Baxter
Journal:  Hum Vaccin Immunother       Date:  2016-07-19       Impact factor: 3.452

Review 9.  Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.

Authors:  Glendie Marcelin; Matthew R Sandbulte; Richard J Webby
Journal:  Rev Med Virol       Date:  2012-03-22       Impact factor: 6.989

10.  On-label and off-label use of high-dose influenza vaccine in the United States, 2010-2012.

Authors:  Leah J McGrath; M Alan Brookhart
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.